Radionetics

Radionetics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.radionetics.com

Last Round

Strategic

Jul 1, 2024

Total Funding Raised

$222.5M

Company Overview

Radionetics Oncology is a biopharmaceutical company specializing in the discovery and development of innovative radiotherapeutics for the treatment of solid tumors, allowing medical professionals to utilize non-peptide and small molecules for delivering therapeutic radioisotopes.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Medical Imaging, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

radiopharmaceuticalsGPCR targetingtheranosticssmall molecule drugsradioligand therapydrug discovery platformGPCRsG-protein coupled receptorstargeted radiotherapyoncology therapeuticsprecision oncologynuclear medicinesolid tumor treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Radionetics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Radionetics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
StrategicJul 1, 2024
Series AJan 3, 2024
SeedOct 18, 2021

Key People

Founding team and executive leadership

Paul Grayson

President And CEO

Executive Team

Alyssa Levin

Chief Financial Officer

Executive Team

Brett Ewald

Chief Operating Officer

Executive Team

Radionetics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 11, 2026

    Announced a strategic agreement with Eli Lilly.

  • Jan 3, 2024

    $53M round completed.

Radionetics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Radionetics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Radionetics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range46
Year Founded2021
Last FundingJul 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.